Summary of COVID-19 cytokine adsorption studies

1. Stockmann et al., CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study

49 patient cytokine adsorption ICU RCT: 9% lower mortality (p=0.79).
RCT 49 COVID-19 patients with vasoplegic shock and multiple organ failure showing no significant difference in shock resolution or mortality with CytoSorb extracorporeal cytokine adsorption compared to standard care.
Feb 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005493, https://c19p.org/stockmann

2. Supady et al., Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial

34 patient cytokine adsorption late treatment RCT: 250% higher mortality (p=0.002).
RCT 34 severe COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO) showing significantly higher mortality with cytokine adsorption therapy.
Jul 2021, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260021001776, https://c19p.org/supady